Medical - Devices
Compare Stocks
4 / 10Stock Comparison
FONR vs DBVT vs ALKS vs AEYE
Revenue, margins, valuation, and 5-year total return — side by side.
Biotechnology
Biotechnology
Software - Application
FONR vs DBVT vs ALKS vs AEYE — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Medical - Devices | Biotechnology | Biotechnology | Software - Application |
| Market Cap | $124M | $1712.35T | $5.90B | $100M |
| Revenue (TTM) | $106M | $0.00 | $1.56B | $40M |
| Net Income (TTM) | $8M | $-168M | $153M | $-3M |
| Gross Margin | 40.8% | — | 65.4% | 78.3% |
| Operating Margin | 10.1% | — | 12.3% | -7.9% |
| Forward P/E | 15.3x | — | 24.8x | — |
| Total Debt | $39M | $22M | $70M | $721K |
| Cash & Equiv. | $56M | $194M | $1.12B | $5M |
FONR vs DBVT vs ALKS vs AEYE — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| FONAR Corporation (FONR) | 100 | 78.9 | -21.1% |
| DBV Technologies S.… (DBVT) | 100 | 40.7 | -59.3% |
| Alkermes plc (ALKS) | 100 | 213.9 | +113.9% |
| AudioEye, Inc. (AEYE) | 100 | 92.8 | -7.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: FONR vs DBVT vs ALKS vs AEYE
Each card shows where this stock fits in a portfolio — not just who wins on paper.
FONR has the current edge in this matchup, primarily because of its strength in income & stability and sleep-well-at-night.
- Dividend streak 0 yrs, beta 0.10
- Lower volatility, beta 0.10, Low D/E 24.3%, current ratio 8.45x
- Beta 0.10, current ratio 8.45x
- Better valuation composite
DBVT is the clearest fit if your priority is momentum.
- +110.4% vs AEYE's -27.9%
ALKS is the #2 pick in this set and the best alternative if quality and efficiency is your priority.
- 9.8% margin vs AEYE's -7.6%
- 5.4% ROA vs DBVT's -89.0%
AEYE is the clearest fit if your priority is growth exposure and long-term compounding.
- Rev growth 14.5%, EPS growth 30.6%, 3Y rev CAGR 10.5%
- 102.2% 10Y total return vs FONR's 35.0%
- 14.5% revenue growth vs DBVT's -100.0%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 14.5% revenue growth vs DBVT's -100.0% | |
| Value | Better valuation composite | |
| Quality / Margins | 9.8% margin vs AEYE's -7.6% | |
| Stability / Safety | Beta 0.10 vs AEYE's 2.29 | |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | +110.4% vs AEYE's -27.9% | |
| Efficiency (ROA) | 5.4% ROA vs DBVT's -89.0% |
FONR vs DBVT vs ALKS vs AEYE — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FONR vs DBVT vs ALKS vs AEYE — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
ALKS leads in 2 of 6 categories
FONR leads 2 • AEYE leads 2 • DBVT leads 0
Explore the data ↓Income & Cash Flow (Last 12 Months)
ALKS leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ALKS and DBVT operate at a comparable scale, with $1.6B and $0 in trailing revenue. ALKS is the more profitable business, keeping 9.8% of every revenue dollar as net income compared to AEYE's -7.6%. On growth, ALKS holds the edge at +28.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $106M | $0 | $1.6B | $40M |
| EBITDAEarnings before interest/tax | $15M | -$112M | $212M | -$504,000 |
| Net IncomeAfter-tax profit | $8M | -$168M | $153M | -$3M |
| Free Cash FlowCash after capex | $6M | -$151M | $392M | $2M |
| Gross MarginGross profit ÷ Revenue | +40.8% | — | +65.4% | +78.3% |
| Operating MarginEBIT ÷ Revenue | +10.1% | — | +12.3% | -7.9% |
| Net MarginNet income ÷ Revenue | +7.1% | — | +9.8% | -7.6% |
| FCF MarginFCF ÷ Revenue | +5.4% | — | +25.1% | +5.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | +2.4% | — | +28.2% | +7.9% |
| EPS Growth (YoY)Latest quarter vs prior year | +6.9% | +91.5% | -4.1% | +29.0% |
Valuation Metrics
FONR leads this category, winning 2 of 5 comparable metrics.
Valuation Metrics
At 15.3x trailing earnings, FONR trades at a 38% valuation discount to ALKS's 24.8x P/E. On an enterprise value basis, FONR's 6.5x EV/EBITDA is more attractive than ALKS's 17.3x.
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $124M | $1712.35T | $5.9B | $100M |
| Enterprise ValueMkt cap + debt − cash | $106M | $1712.35T | $4.9B | $96M |
| Trailing P/EPrice ÷ TTM EPS | 15.35x | -0.76x | 24.76x | -32.36x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | 6.52x | — | 17.25x | — |
| Price / SalesMarket cap ÷ Revenue | 1.19x | — | 4.00x | 2.49x |
| Price / BookPrice ÷ Book value/share | 0.77x | 0.66x | 3.28x | 20.91x |
| Price / FCFMarket cap ÷ FCF | 16.61x | — | 12.28x | — |
Profitability & Efficiency
ALKS leads this category, winning 7 of 9 comparable metrics.
Profitability & Efficiency
ALKS delivers a 8.8% return on equity — every $100 of shareholder capital generates $9 in annual profit, vs $-130 for DBVT. ALKS carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to FONR's 0.24x. On the Piotroski fundamental quality scale (0–9), FONR scores 7/9 vs AEYE's 4/9, reflecting strong financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | +4.3% | -130.2% | +8.8% | -47.8% |
| ROA (TTM)Return on assets | +3.5% | -89.0% | +5.4% | -9.5% |
| ROICReturn on invested capital | +6.1% | — | +18.9% | -42.4% |
| ROCEReturn on capital employed | +5.9% | -145.7% | +14.2% | -17.7% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 4 | 7 | 4 |
| Debt / EquityFinancial leverage | 0.24x | 0.13x | 0.04x | 0.15x |
| Net DebtTotal debt minus cash | -$17M | -$172M | -$1.0B | -$5M |
| Cash & Equiv.Liquid assets | $56M | $194M | $1.1B | $5M |
| Total DebtShort + long-term debt | $39M | $22M | $70M | $721,000 |
| Interest CoverageEBIT ÷ Interest expense | 705.24x | -189.82x | 32.30x | -2.79x |
Total Returns (Dividends Reinvested)
AEYE leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ALKS five years ago would be worth $16,091 today (with dividends reinvested), compared to $3,090 for DBVT. Over the past 12 months, DBVT leads with a +110.4% total return vs AEYE's -27.9%. The 3-year compound annual growth rate (CAGR) favors AEYE at 6.4% vs FONR's 4.6% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | +1.9% | +4.9% | +25.3% | -18.7% |
| 1-Year ReturnPast 12 months | +53.4% | +110.4% | +16.5% | -27.9% |
| 3-Year ReturnCumulative with dividends | +14.3% | +19.7% | +14.5% | +20.6% |
| 5-Year ReturnCumulative with dividends | +9.8% | -69.1% | +60.9% | -60.2% |
| 10-Year ReturnCumulative with dividends | +35.0% | -87.0% | -11.0% | +102.2% |
| CAGR (3Y)Annualised 3-year return | +4.6% | +6.2% | +4.6% | +6.4% |
Risk & Volatility
FONR leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
FONR is the less volatile stock with a 0.10 beta — it tends to amplify market swings less than AEYE's 2.29 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. FONR currently trades 99.6% from its 52-week high vs AEYE's 49.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.09x | 1.26x | 1.00x | 2.18x |
| 52-Week HighHighest price in past year | $18.95 | $26.18 | $36.60 | $16.39 |
| 52-Week LowLowest price in past year | $12.17 | $7.53 | $25.17 | $5.31 |
| % of 52W HighCurrent price vs 52-week peak | +99.6% | +76.3% | +96.7% | +49.4% |
| RSI (14)Momentum oscillator 0–100 | 67.7 | 48.1 | 60.2 | 61.3 |
| Avg Volume (50D)Average daily shares traded | 52K | 252K | 2.3M | 194K |
Analyst Outlook
AEYE leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: DBVT as "Buy", ALKS as "Buy". Consensus price targets imply 131.8% upside for DBVT (target: $46) vs 29.9% for ALKS (target: $46).
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Buy | — |
| Price TargetConsensus 12-month target | — | $46.33 | $46.00 | — |
| # AnalystsCovering analysts | — | 15 | 28 | — |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | 0 | 0 | 0 | 1 |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +1.5% | 0.0% | +0.5% | 0.0% |
ALKS leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). FONR leads in 2 (Valuation Metrics, Risk & Volatility).
FONR vs DBVT vs ALKS vs AEYE: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is FONR or DBVT or ALKS or AEYE a better buy right now?
For growth investors, AudioEye, Inc.
(AEYE) is the stronger pick with 14. 5% revenue growth year-over-year, versus -5. 2% for Alkermes plc (ALKS). FONAR Corporation (FONR) offers the better valuation at 15. 3x trailing P/E, making it the more compelling value choice. Analysts rate DBV Technologies S. A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — FONR or DBVT or ALKS or AEYE?
On trailing P/E, FONAR Corporation (FONR) is the cheapest at 15.
3x versus Alkermes plc at 24. 8x.
03Which is the better long-term investment — FONR or DBVT or ALKS or AEYE?
Over the past 5 years, Alkermes plc (ALKS) delivered a total return of +60.
9%, compared to -69. 1% for DBV Technologies S. A. (DBVT). Over 10 years, the gap is even starker: AEYE returned +96. 5% versus DBVT's -87. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — FONR or DBVT or ALKS or AEYE?
By beta (market sensitivity over 5 years), FONAR Corporation (FONR) is the lower-risk stock at 0.
09β versus AudioEye, Inc. 's 2. 18β — meaning AEYE is approximately 2451% more volatile than FONR relative to the S&P 500. On balance sheet safety, Alkermes plc (ALKS) carries a lower debt/equity ratio of 4% versus 24% for FONAR Corporation — giving it more financial flexibility in a downturn.
05Which is growing faster — FONR or DBVT or ALKS or AEYE?
By revenue growth (latest reported year), AudioEye, Inc.
(AEYE) is pulling ahead at 14. 5% versus -5. 2% for Alkermes plc (ALKS). On earnings-per-share growth, the picture is similar: AudioEye, Inc. grew EPS 30. 6% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, AEYE leads at 10. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — FONR or DBVT or ALKS or AEYE?
Alkermes plc (ALKS) is the more profitable company, earning 16.
4% net margin versus -7. 6% for AudioEye, Inc. — meaning it keeps 16. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALKS leads at 17. 2% versus -7. 9% for AEYE. At the gross margin level — before operating expenses — ALKS leads at 86. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Which pays a better dividend — FONR or DBVT or ALKS or AEYE?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is FONR or DBVT or ALKS or AEYE better for a retirement portfolio?
For long-horizon retirement investors, FONAR Corporation (FONR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
09)). AudioEye, Inc. (AEYE) carries a higher beta of 2. 18 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (FONR: +34. 7%, AEYE: +96. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between FONR and DBVT and ALKS and AEYE?
These companies operate in different sectors (FONR (Healthcare) and DBVT (Healthcare) and ALKS (Healthcare) and AEYE (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: FONR is a small-cap deep-value stock; DBVT is a mega-cap quality compounder stock; ALKS is a small-cap quality compounder stock; AEYE is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.